CD169

Breg CD169 TLS Treg breast cancer lymph node macrophage

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
16 Feb 2023
Historique:
received: 24 01 2023
revised: 13 02 2023
accepted: 13 02 2023
entrez: 25 2 2023
pubmed: 26 2 2023
medline: 26 2 2023
Statut: epublish

Résumé

The presence of CD169

Identifiants

pubmed: 36831605
pii: cancers15041262
doi: 10.3390/cancers15041262
pmc: PMC9954705
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Swedish Research Council
ID : 2020-01842
Organisme : Swedish Cancer Society
ID : 21 1392 Pj 01 H
Organisme : Malmö allmänna sjukhuset (MAS) för bekämpande av cancer foundation
ID : 2021-2022
Organisme : Gyllenstiernska Krapperups Foundation
ID : KR 2018-0069
Organisme : Regional grants from the Swedish state under the agreement between the Swedish government and the county councils the ALF-agreement
ID : 2018-Projekt 0059

Références

Hereditary Genet. 2013;2013(Suppl 2):
pubmed: 25285241
Oncologist. 2017 Nov;22(11):1316-1324
pubmed: 28701569
Pathol Int. 2018 Dec;68(12):685-693
pubmed: 30516869
Target Oncol. 2020 Aug;15(4):415-428
pubmed: 32514907
Cancer Sci. 2018 May;109(5):1723-1730
pubmed: 29520898
Sci Rep. 2015 Oct 14;5:15179
pubmed: 26462617
Curr Oncol. 2021 May 11;28(3):1803-1822
pubmed: 34064867
Cell. 2022 May 26;185(11):1924-1942.e23
pubmed: 35525247
Breast Cancer Res Treat. 2012 Feb;131(3):939-47
pubmed: 22094937
Front Immunol. 2020 Aug 04;11:1731
pubmed: 32849616
Cancer Sci. 2016 Jun;107(6):846-52
pubmed: 26991548
Cancer Res. 2009 Mar 1;69(5):2000-9
pubmed: 19244125
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Immunotherapy. 2013 Oct;5(10):1075-87
pubmed: 24088077
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
J Clin Pathol. 2016 May;69(5):422-30
pubmed: 26475777
Eur J Immunol. 2022 Oct;52(10):1581-1594
pubmed: 35907260
Cancer Immunol Res. 2015 Dec;3(12):1356-63
pubmed: 26297710
Signal Transduct Target Ther. 2021 Feb 20;6(1):72
pubmed: 33608497
J Innate Immun. 2012;4(5-6):424-36
pubmed: 22488251
Front Immunol. 2021 Mar 08;12:620510
pubmed: 33763066
Cancer Cell Int. 2021 Oct 15;21(1):536
pubmed: 34654433
Immunity. 2002 Sep;17(3):239-50
pubmed: 12354378
Genome Med. 2015 Feb 02;7(1):20
pubmed: 25722745
Front Immunol. 2017 Jun 30;8:767
pubmed: 28713385
Cell Death Dis. 2016 Nov 3;7(11):e2446
pubmed: 27809306
J Virol. 2015 May;89(9):4748-59
pubmed: 25673724
JCO Precis Oncol. 2018 Mar 09;2:
pubmed: 32913985
Immunity. 2019 Jun 18;50(6):1453-1466.e4
pubmed: 31053503
Breast Cancer. 2019 Mar;26(2):180-189
pubmed: 30244409
Breast Cancer Res. 2021 Feb 18;23(1):27
pubmed: 33602289
Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2491-6
pubmed: 22308361
Mol Oncol. 2014 Feb;8(1):119-28
pubmed: 24287398
Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4215-20
pubmed: 24591636
J Clin Oncol. 2009 Mar 10;27(8):1160-7
pubmed: 19204204
Oncoimmunology. 2020 Nov 22;9(1):1848067
pubmed: 33299660
PLoS Pathog. 2013;9(4):e1003291
pubmed: 23593001
Immunity. 2019 Jun 18;50(6):1467-1481.e6
pubmed: 31201093
Eur J Immunol. 2020 Nov;50(11):1757-1769
pubmed: 32529638
Immunol Rev. 2017 Mar;276(1):178-191
pubmed: 28258691
Trends Immunol. 2012 Feb;33(2):66-70
pubmed: 22192781
Front Immunol. 2019 Feb 28;10:347
pubmed: 30891035
Oncoimmunology. 2016 Apr 29;5(7):e1177690
pubmed: 27622027
Immunity. 2015 Sep 15;43(3):579-90
pubmed: 26341400
BMC Cancer. 2015 Mar 06;15:101
pubmed: 25884667
Biomed Rep. 2021 Feb;14(2):26
pubmed: 33408860
Front Immunol. 2016 Oct 03;7:407
pubmed: 27752258
Cancer Lett. 2016 Jan 1;370(1):85-90
pubmed: 26477683
Front Immunol. 2021 Jul 28;12:697840
pubmed: 34394090
Hum Immunol. 2016 Feb;77(2):201-13
pubmed: 26686412
J Pathol. 2016 Jun;239(2):231-41
pubmed: 27174787

Auteurs

Oscar Briem (O)

Cancer Immunology, Department of Translational Medicine, Lund University, 214 28 Malmö, Sweden.

Eva Källberg (E)

Cancer Immunology, Department of Translational Medicine, Lund University, 214 28 Malmö, Sweden.

Siker Kimbung (S)

Division of Oncology, Department of Clinical Sciences, Lund University, 223 81 Lund, Sweden.

Srinivas Veerla (S)

Division of Oncology, Department of Clinical Sciences, Lund University, 223 81 Lund, Sweden.

Jenny Stenström (J)

Division of Clinical Genetics, Department of Laboratory Medicine Lund, Lund University, 221 84 Lund, Sweden.

Thomas Hatschek (T)

Department of Oncology and Pathology, Karolinska Institutet, 171 77 Solna, Sweden.

Catharina Hagerling (C)

Division of Clinical Genetics, Department of Laboratory Medicine Lund, Lund University, 221 84 Lund, Sweden.

Ingrid Hedenfalk (I)

Division of Oncology, Department of Clinical Sciences, Lund University, 223 81 Lund, Sweden.

Karin Leandersson (K)

Cancer Immunology, Department of Translational Medicine, Lund University, 214 28 Malmö, Sweden.

Classifications MeSH